Drugmakers are re-examining products they developed years ago to treat influenza now that authorities are issuing warnings worldwide about a possible pandemic and are concerned about drug shortages. A previous lack of commercial interest slowed the development of some drugs that showed efficacy in lab tests, one expert said. One candidate is BioCryst Pharmaceuticals' peramivir, which was ineffective in clinical trials as an oral drug, but now is undergoing new tests as a drug given intravenously or by injection.

Full Story:

Related Summaries